New research, led by Li Ding, PhD, shows that current genome analysis approaches systematically miss detecting a certain type of complex mutation in cancer patients’ tumors. A significant percentage of these complex mutations are found in well-known cancer genes that could be targeted by existing drugs, potentially expanding the number of cancer patients who may benefit.
High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.
Rohit Pappu, PhD, the Edwin H. Murty Professor of Engineering at Washington University’s School of Engineering & Applied Science, will help spearhead the newly formed Human Dark Proteome Initiative, launched Nov. 9 by St. Jude Children’s Research Hospital and The Scripps Research Institute.
A team of engineers, led by Washington University’s Lihong Wang and postdoctoral researcher Junjie Yao, found that by genetically modifying glioblastoma cancer cells to express BphP1 protein, derived from a bacterium commonly found in soil and water, they could clearly see tiny amounts of live cancer cells as deep as 1 centimeter in tissue using photoacoustic tomography.
Cancers have many strategies for avoiding attacks from the immune system. But the more scientists are able to understand about them, the more effectively they will be able to use the immune system to fight cancer. To that end, researchers at Washington University School of Medicine in St. Louis have identified a new strategy.
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. The research is a boost to cancer immunotherapy, a treatment strategy that unleashes the immune system to seek out and destroy cancer.
In cells lining the airway, high levels of certain proteins have long been linked with the overproduction of mucus characteristic of diseases like asthma and COPD. New research from the School of Medicine provides clues to potentially counteract inappropriate mucus production.
Researchers led by Samuel Achilefu, PhD, at the School of Medicine have devised a way to apply light-based therapy to deep tissues never before accessible. Instead of shining an outside light, they delivered light directly to tumor cells, along with a photosensitive source of free radicals that can be activated by the light to destroy cancer.
In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at the School of Medicine including senior author Robert Schreiber, PhD, has brought the approach one step closer to reality.
Lihong Wang, PhD, the Gene K. Beare Distinguished Professor of Biomedical Engineering at the School of Engineering & Applied Science is applying a novel time-reversal technology that allows researchers to better focus light in tissue, such as muscles and organs.